Research Area: Synthetic Organic Medicinal Chemistry
Anticancer Drug Discovery: Targets - Kinases (PI3K-AKT-mTOR, BRAF, KRAS, VEGFR, and their cross-talks), Ferroptosis, Apoptosis, Angiogenesis, tumor vascular normalization, Immunotherapy (ICI TME, and TMB) especially for cold tumor cases in Indian patients; DNA topoisomerase IIα, Microtubule-dynamics; Cancers - Pancreatic, Breast, Non-small cell lung cancer (NSCLC), Oral and Gastrointestinal malignancies.
Antibacterial Drug Discovery: Design and synthesis of heterocyclic compounds as target-specific antibacterial agents.
Creating New Therapeutics: Molecular engineering of drugs and clinical trial agents; Exploration of patentable bioactive chemotypes, Preclinical agents.
Medicinal Chemistry Strategies: Network-linked polypharmacology; Natural product-inspired, Scaffold-hopping, and Choice-based change approaches.
Medicinal Chemistry Exploration: Identification of target-specific unique pharmacophore motifs; Structural modulations linked to pharmacodynamics, drug-likeness and pharmacokinetic-relevant physicochemical properties.
Synthesis: Discovery of molecular-diversity feasible routes for synthesis of design-focused target-specific inhibitors, natural product-based compounds (structural elaborated, simplified, inspired, and scaffold-hopped analogs).
Organic Chemistry and New Methods: Construction of pharmaceutically privileged heterocyclic molecular skeletons, C-H bond functionalization, DAC chemistry, Ylide chemistry, Synthon concept, Isocyanide-based reactions, Catalysis, Green chemistry.